Nts in Any Remedy GroupPatients with Adverse Event (AE), (n) Any AE Cognitive disorder Disturbance in focus Dizziness Migraine Paraesthesia Sinusitis Nausea Neck discomfort Fatigue Depression Vision blurred Decreased appetite 2.7 (six) 0 7.0 (10) ten.6 (15) five.0 (14) 5.3 (15) 3.8 (3) 0 five.5 (12) 0.five (1) four.five (ten) 0.5 (1) 1.8 (four) six.three (9) 13.4 (19) 2.1 (three) 13.four (19) 5.six (eight) two.7 (six) 2.7 (six) 0.five (1) 12.7 (18) 2.1 (three) 31.0 (44) 8.2 (23) 2.five (7) 16.0 (45) 5.7 (16) 7.1 (20) 4.3 (12) 7.1 (20) three.five (10) 1.three (1) 5.0 (4) 0 six.3 (5) 0 six.3 (5) 0 two.five (2) OnabotulinumtoxinA (n=220) Topiramate Total Switched to (n=142) (N=282) OnabotulinumtoxinA (n=80)P10 Chronic migraine therapy with erenumab: Responder rates Hans-Christoph Diener1, Jan Brandes2, David Dolezil3, Marshall C Freeman4, Peter J McAllister5, Paul Winner6, Sunfa Cheng7, Dean K Leonardi7, Robert A Lenz7, Daniel D Mikol7 1 University Duisburg-Essen, Essen, Germany; 2Nashville Neuroscience Group, Nashville, TN, USA; 3Prague Headache Center, DADO Medical s.r.o., Prague, Czech Republic; 4Headache Wellness Center, Greensboro, NC, USA; 5New England Institute for Neurology and Headache, Stamford, CT, USA; 6Palm Beach Headache Center, West Palm Beach, FL, USA; 7 Amgen Inc., Thousand Oaks, CA, USA Correspondence: Hans-Christoph Diener ([email protected]) The Journal of Headache and Discomfort 2017, 18(Suppl 1):P10 Background Erenumab (AMG 334) is often a human anti-calcitonin gene-related peptide (CGRP) receptor antibody being evaluated as preventive therapy for chronic migraine (CM). When assessing efficacy of CM therapies by responder prices, there is certainly an unmet require for additional efficient treatment options. Strategies Within a prospective exploratory evaluation of information from a phase two study (NCT02066415) in sufferers with CM (15 headache daysmonth more than 3 months with 8 migraine days), Boldenone Cypionate Biological Activity individuals (N=667) have been randomised to erenumab (70 mg or 140 mg after monthly) or placebo. This analysis integrated calculation of Bromoxynil octanoate custom synthesis proportions of sufferers with 50 , 75 , or one hundred reduction in month-to-month migraine days (MMD) from baseline to final 4 weeks of a 12-week double-blind phase. P-values are according to odds ratios (ORs) from placebo and are not adjusted for a number of comparisons. Final results Imply (SD) baseline MMD had been 18.0 (four.6). Considerably greater proportions of sufferers treated with erenumab 70 mg or 140 mg skilled a 50 reduction from baseline in MMD compared with placebo at Week 12 (39.9 and 41.2 , vs 23.five ; OR: two.two [p0.001] and 2.three [p0.001]). The 75 responder rates were higher for sufferers treated with erenumab 70 mg or 140 mg compared with placebo (17.0 and 20.9 , vs 7.8 ; OR: two.four [p=0.002] and three.1 [p0.001]). Likewise, the one hundred responder prices had been greater for individuals treated with erenumab 70 mg or 140 mg compared with placebo (4.three and 2.7 , vs 0.4 ; OR: 12.six [p=0.002] and 8.1 [p=0.026]). Conclusions Erenumab remedy resulted in higher proportions of individuals with CM experiencing 50 , 75 , and one hundred reduction in MMD as compared with placebo.45.five (one hundred) 0.5 (1)76.eight (109) 12.7 (18) 7.7 (11)62.four (176) 6.four (18) 3.9 (11)41.3 (33) 1.3 (1)P11 Systematic Cochrane evaluation of botulinum toxins for the prevention of migraine in adults Alexandra Sinclair1, Clare P Herd2, Claire L Tomlinson3, Caroline Rick3, WJ Scotton1, Julie Edwards4, Natalie Ives3, Carl E Clarke2 1 Institute of Metabolism and Systems Analysis, University of Birmingham, Birmingham, UK; 2Institute of Applied Wellness Research, University of Birmingham, Birmingham, UK; 3Birmingham Clinical T.